Beam Therapeutics Shareholders Approve All Proposals at 2026 Annual Meeting

Beam Therapeutics announced the official voting results from its 2026 annual meeting of stockholders held on June 3, 2026. All proposals presented to shareholders were approved, including the election of three Class III directors, the ratification of the company's independent auditor, and a non-binding advisory vote on executive compensation.

Key Details

• Election of Directors: John Evans, John Maraganore, Ph.D., and Christi Shaw were elected as Class III directors to serve until the company's 2029 annual meeting.
• Auditor Ratification: Shareholders ratified the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Executive Compensation: The compensation for the company's named executive officers was approved on an advisory, non-binding basis.